<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360945</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000482280</org_study_id>
    <secondary_id>CCLG-CNS-2004-02</secondary_id>
    <secondary_id>EU-20622</secondary_id>
    <nct_id>NCT00360945</nct_id>
  </id_info>
  <brief_title>Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma</brief_title>
  <official_title>Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and temozolomide, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving cisplatin together with temozolomide&#xD;
      works in treating young patients with malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate (complete and partial response) in pediatric&#xD;
           patients with malignant gliomas treated with temozolomide and cisplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Identify genetic, metabolic, and proteomic profiles that will provide an insight into&#xD;
           the molecular pathways involved in the pathogenesis of these tumors.&#xD;
&#xD;
        -  Link genetic changes with clinical details, histopathology, and patient outcome, thereby&#xD;
           developing a biological basis for diagnosis, prognosis, and treatment monitoring.&#xD;
&#xD;
        -  Evaluate relapse-free survival at 1 and 2 years in patients treated at diagnosis.&#xD;
&#xD;
        -  Evaluate the duration of clinical response in patients treated at relapse.&#xD;
&#xD;
        -  Study the health status and quality of life of these patients.&#xD;
&#xD;
        -  Evaluate long-term toxicity of this therapeutic combination.&#xD;
&#xD;
        -  Evaluate the ability of magnetic resonance spectroscopy vs CT scan to predict response&#xD;
           in patients with high-grade astrocytomas.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label, nonrandomized, parallel-group study. Patients are&#xD;
      stratified according to disease status (newly diagnosed vs relapsed). Patients with newly&#xD;
      diagnosed disease are further stratified according to spread of disease (localized and&#xD;
      measurable vs diffuse unmeasurable).&#xD;
&#xD;
        -  Stratum I (newly diagnosed disease): Patients receive CISTEM chemotherapy comprising&#xD;
           cisplatin IV over 3 hours on day 1 and oral temozolomide once daily on days 2-6.&#xD;
           Treatment repeats every 28 days for up to 7 courses. Patients who achieve responsive or&#xD;
           stable disease after 2 courses receive 2 more courses of CISTEM chemotherapy and then&#xD;
           undergo radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy,&#xD;
           patients may receive up to 3 more courses of CISTEM chemotherapy for a total of 7&#xD;
           courses.&#xD;
&#xD;
        -  Stratum II (relapsed disease): Patients receive CISTEM chemotherapy for up to 7 courses&#xD;
           as in stratum I. Patients who reach the maximum dose allowed for cisplatin may receive&#xD;
           oral temozolomide alone indefinitely.&#xD;
&#xD;
      Tissue and blood samples are obtained at baseline and examined by immunohistochemistry,&#xD;
      fluorescent in situ hybridization (FISH), and loss of heterozygosity. The tumor tissue is&#xD;
      analyzed for p53, MSH2, MLH1, and MGMT.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 87 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate after 2 courses</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response in patients receiving more than 2 courses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression at 6 months and 1 and 2 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">87</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>loss of heterozygosity analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of 1 of the following grade III or&#xD;
             grade IV malignant glial tumors*:&#xD;
&#xD;
               -  Glioblastoma&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Anaplastic oligoastrocytoma&#xD;
&#xD;
               -  Anaplastic ganglioglioma&#xD;
&#xD;
               -  Anaplastic mixed tumor&#xD;
&#xD;
                    -  Glial component is essential NOTE: *Malignant gliomas occurring as a second&#xD;
                       primary malignancy allowed&#xD;
&#xD;
          -  Newly diagnosed or recurrent disease&#xD;
&#xD;
          -  No malignant brain stem tumors&#xD;
&#xD;
          -  Incompletely resected tumors&#xD;
&#xD;
               -  No completely resected tumors&#xD;
&#xD;
          -  Measurable or evaluable disease by conventional MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Lansky performance status 40-100%&#xD;
&#xD;
          -  Organ toxicity ≤ grade 2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Prothrombin ≥ 50%&#xD;
&#xD;
          -  Fibrinogen ≥ 1.5 g/L&#xD;
&#xD;
          -  Creatinine normal for age&#xD;
&#xD;
               -  Creatinine ≤ 65 µmol/L (4-15 years of age)&#xD;
&#xD;
               -  Creatinine ≤ 110 µmol/L (15-20 years of age)&#xD;
&#xD;
          -  Audiogram with toxicity grade ≤ 2&#xD;
&#xD;
          -  ECG normal&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No severe or life-threatening infection&#xD;
&#xD;
          -  No uncontrolled developing or symptomatic intracranial hypertension&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) or radiotherapy&#xD;
             for patients with relapsed disease&#xD;
&#xD;
          -  No prior cisplatin or temozolomide&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Lowis, MD, PhD, BA, MRCP, MRCPCH</last_name>
    <affiliation>Bristol Royal Hospital for Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Grill, MD, PhD</last_name>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Michalski, MD</last_name>
    <affiliation>Great Ormond Street Hospital for Children NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A. Walker</last_name>
    <affiliation>Queen's Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlesex Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1T 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester and Manchester Children's University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital NHS Trust</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

